Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Atezolizumab-Based Combination Therapy in Localized Prostate Cancer
NCT03821246Phase 2Recruiting
- Start
- Oct 2019
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab in prostate cancer (PCa) (3 cohorts). Primary endpoint: Proportion of subjects who demonstrate a positive response at 12 months. Started Oct 2019; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03821246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03821246.